Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trialBrian G. Feagan, Rupert W. Leong, Marion Vetter et al.|The Lancet. Gastroenterology & hepatology|2023Cited by 235
Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through studyMarc Ferrante, Luciana Teixeira de Campos, Geert D’Haens et al.|The Lancet|2024Cited by 107